Banner

IOP-lowering efficacy of bimatoprost, latanoprost weighed

Article

Bimatoprost 0.03% (Lumigan, Allergan) offers more efficacy than latanoprost 0.005% (Xalatan, Pharmacia) for lowering elevated IOP and is similarly well tolerated, according to the results of a 6-month, multicenter, randomized, double-masked study.

Related Videos
Related Content

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Shine on social media like ModaMD: Real World Ophthalmology

September 21st 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

September 13th 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023

Prevent Blindness joins World Sight Day global initiative of “Love Your Eyes At Work”

September 20th 2023

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Shine on social media like ModaMD: Real World Ophthalmology

September 21st 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

September 13th 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023

Prevent Blindness joins World Sight Day global initiative of “Love Your Eyes At Work”

September 20th 2023

Macular leakage is important in diabetic eye disease outcomes

September 21st 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Shine on social media like ModaMD: Real World Ophthalmology

September 21st 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

September 13th 2023

Disparities remain an obstacle to health equity in eye care

September 20th 2023

Prevent Blindness joins World Sight Day global initiative of “Love Your Eyes At Work”

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.